This lower off-target background together with lower variance of tracer binding in PSP target regions of healthy controls for 18F-PI-2620 compared with that of earlier tau PET tracers8,23 might lead to higher effect sizes in PSP diagnosis. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.